News of Note—Kite’s CAR-T; New Flex CEO; InVivo trial delay

Kite hoping to fly in Europe as Flex gets a new chief and InVivo halts enrollment

> Kite Pharma is slightly lagging behind Novartis in the U.S. race to market the first ever CAR-T med, but it is hoping to be the first in Europe after filing a new application for axicabtagene ciloleucel. The biotech is seeking licences for patients with relapsed/refractory diffuse large B-cell lymphoma, transformed follicular lymphoma and primary mediastinal B-cell lymphoma. Release

> Flex Pharma has hired William McVicar, Ph.D., as its new president and CEO. The tiny biotech announced last month that co-founder Christoph Westphal, M.D., Ph.D., was stepping down from his chief role, coming after a trial setback for FLX-787 in nocturnal leg cramps. Statement

> InVivo Therapeutics has halted enrollment in its Inspire study of neuro-spinal scaffold in patients with complete thoracic spinal cord injury after a sudden death. This is now the third death from the trial, and although all three are believed to be unrelated to the therapy, the company has stopped recruitment while it talks with the FDA. Release

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.